Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
181
resultados
Última actualización
18/03/2026 [07:49:00]
Resultados 50 a 75 de 181
Resumen de: WO2024176230A1
The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.
Resumen de: CN121196614A
The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.
Resumen de: US2025389717A1
The present disclosure provides methods for assessing mucosal healing in a patient with Crohn's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.
Resumen de: CN121194794A
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are methods of increasing T regulatory (Treg) cells or decreasing T helper 17 (Th17) cells. The methods involve administering to the subject a lactophilic lipoprotein A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing. These methods are useful for treating diseases with autoimmune and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, autoimmune or inflammatory nervous system disease, antibody-mediated transplant rejection, infant cholestasis, hemophagocytic lymphocythemia, erythrocytophagocythemia, malnutrition, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia, hyperplasia and hyperplasia. The traditional Chinese medicine composition is beneficial to patients suffering from systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2024240709A1
The present invention relates to methods of immunoassay for detecting HNE-generated fragments of the α1 chain of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. The present invention also relates to monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2025257752A1
This invention relates to methods of detecting inflammatory disease in a subject by detecting circulating microclots, based on combined detection or co-detection of fibrin amyloid microclots and components from Neutrophil Extracellular Traps in a sample from the subject, wherein an increased presence of fibrin amyloid microclots and NETs in the sample compared to a control or reference value is indicative of inflammatory disease in the subject. The invention also relates to kits for detecting circulating microclots to be used in the methods of detecting inflammatory disease.
Resumen de: WO2025259880A1
Provided herein are materials and methods for determining responsiveness of any therapy that enhances regulatory T cell (Treg) function in the treatment of inflammatory bowel disease (IBD). The materials and methods provided herein may be used to determine low dose IL- 2 responsiveness in a subject having an inflammatory bowel disease. The materials and methods can be used to determine low dose IL- 2 responsiveness in a blood sample prior to administering a low dose IL-2 therapy.
Resumen de: EP4663746A2
This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
Resumen de: CN121148713A
The invention discloses a differential diagnosis model (BC-ACTUAL) for Crohn's disease and gastrointestinal behcet disease and application of the differential diagnosis model. Specifically, the invention discloses application of an index combination (Age, C4, TP, UA, ALP and LDH) or a reagent for detecting the index combination in preparation of a product for differential diagnosis of Crohn's disease and gastrointestinal behcet disease. The invention also discloses a logistic regression model established by using the index combination and a scoring system. The model has the characteristics of high sensitivity, good specificity, economy, high efficiency and convenience, can accurately identify and diagnose the Crohn's disease and the gastrointestinal Behcet's disease, is suitable for clinically identifying the Crohn's disease and the gastrointestinal Behcet's disease, helps a clinician to preliminarily distinguish the Crohn's disease and the gastrointestinal Behcet's disease under the condition that only common laboratory indexes are used, and improves the detection accuracy of the Crohn's disease and the gastrointestinal Behcet's disease. The situation that the optimal treatment opportunity of a patient is delayed due to misdiagnosis can be avoided, optimal disease management is achieved, and the good clinical application value is achieved.
Resumen de: CN121142055A
The invention discloses application of protecting histidine as a biomarker in predicting the treatment effect of patients with inflammatory bowel diseases. By detecting the histidine level in the plasma of the patient with the inflammatory bowel disease, the responsiveness of the patient with the inflammatory bowel disease to the thiopurine medicine can be effectively predicted in the initial treatment stage, then the treatment effect of the patient is predicted, formulation of an individualized treatment scheme is achieved, and the treatment accuracy and effectiveness are remarkably improved; the invention further provides application of histidine in preparation of a product for reducing the inflammation level, the TNF-alpha level can be effectively reduced by additionally adding histidine in the treatment process, and then the anti-inflammation effect is achieved.
Resumen de: CN121108103A
In meat freshness evaluation, biogenic amines, especially cadaverine, are key indexes. The novel fluorescent probe ZY1 provided by the invention reacts with cadaverine to realize efficient and rapid detection of meat freshness. The probe has excellent selectivity and ultralow detection limit (LDD = 13.8 nM), and is accompanied by remarkable fluorescence color conversion (light red to bright green). Based on the characteristic, the ZY1 is innovatively integrated with RGB analysis software of a smart phone, and a reliable linear relation between a G/B value and food preservation time is established by shooting a meat extracting solution loaded with the ZY1, so that real-time and portable detection of the food freshness is realized. In view of specific up-regulation of cadaverine biosynthesis in ulcerative colitis (UC), the research further proves the application potential of ZY1 in UC noninvasive auxiliary diagnosis. In addition, ZY1 also shows expanded application in the technical fields of preparation of novel fluorescent materials and information transmission.
Resumen de: WO2025253423A1
A new microbial consortium for use in a rapid screening method for irritable bowel syndrome (IBS) and possibly as a target for the therapeutic treatment of an IBS condition in a subject.
Resumen de: US2025376514A1
The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL-17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
Resumen de: WO2025253316A1
The present disclosure relates to the use of angiotensin-converting enzyme and/or angiotensin-converting enzyme 2 as a fecal biomarker for the diagnosis of a disease or disorder related to the renin-angiotensin-aldosterone system, and also to the use of angiotensin-converting enzyme and angiotensin-converting enzyme 2 isoforms as fecal biomarkers for the detection of dysbiosis.
Resumen de: AU2024260758A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: CN121087164A
The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.
Resumen de: CN121081471A
The invention relates to the field of biological pharmacy, and provides application of CHI3L1 in preparation of medicines for diagnosing and treating ulcerative colitis. The invention discloses an application of a CHI3L1 inhibitor (K284-6111) in development of a medicine for preventing and treating UC, and an application of a reagent for detecting the expression level of CHI3L1 in development of a UC diagnostic tool. The effect of K284-6111 in UC treatment is explored through a DSS-induced mouse model, and a new UC treatment method is provided. The invention provides a high-specificity biomarker for UC diagnosis and application of the high-specificity biomarker in UC prevention and treatment.
Resumen de: CN121065326A
The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.
Resumen de: AU2024273758A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: US2025366831A1
A system and a method for diagnosis and monitoring of inflammatory bowel diseases (IBD) in a subject are provided. The system includes a memory and a control system. The memory stores machine-readable instructions. The control system includes one or more processors configured to execute the machine-readable instructions. Ultrasound image data associated with the gastrointestinal tract of the subject is received. The received ultrasound image data is processed to output a set of ultrasound image features. The output set of ultrasound image features is received, as an input to an automated algorithm. A set of radiomic features is extracted from the input set of ultrasound image features, using the automated algorithm. The ultrasound image data is classified as normal or abnormal based on the extracted set of radiomic features, the classifying being an output of the automated algorithm.
Resumen de: WO2025250163A1
Apparatus and associated methods relate to evaluating impurity content in battery materials. In an illustrative example, a battery material impurity assessment system (BMIAS) may include a slurry mixing system and an impurity extraction system (IBS). The slurry mixing system, for example, may include a motor configured to rotate a vertical axis of a slurry container. For example, the motor may pause a movement of the slurry container when the vertical axis is rotated at a predetermined angle. For example, the IBS may include a translatable magnetic mass (TMM) enclosed within a sheath. For example, by operating a position of the TMM, the IBS may release non-target impurity and retain target substances. In some implementations, the target substance may be ionized by an acid treatment solution rapidly without direct heating. In some implementations, the target substances may be dispersed on a conductive filter to be directly used in subsequent analysis. Various embodiments may advantageously rapid high precision and rapid impurity testing for battery manufacturing.
Nº publicación: KR20250169505A 03/12/2025
Solicitante:
서울대학교병원주식회사바이오뱅크힐링
Resumen de: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
BOPI
Sede Electrónica
